Topical administration of EGF suppresses immune response and protects skin barrier in DNCB-induced atopic dermatitis in NC/Nga mice

Young-Je Kim, Mi Ji Choi, Dong-Ho Bak, Byung Chul Lee, Eun Jung Ko, Ga Ram Ahn, Seung Won Ahn, Moo Joong Kim, Jungtae Na & Beom Joon Kim

Atopic dermatitis (AD) is a common inflammatory skin disease characterized by complex, heterogeneous pathogenesis including skin barrier dysfunction, immunology, and pruritus. Although epidermal growth factor (EGF) is essential for epithelial homeostasis and wound healing, the effect of EGF on AD remains to be explored. To develop a new therapy for AD, the anti-AD potential of EGF was investigated by inducing AD-like skin lesions in NC/Nga mice using 2,4-dinitrochlorobenzene (DNCB). EGF was administrated to NC/Nga mice to evaluate its therapeutic effect on DNCB-induced AD. EGF treatment improved dermatitis score, ear thickness, epidermal hyperplasia, serum total immunoglobulin E level, and transepidermal water loss in NC/Nga mice with DNCB-induced AD. In addition, levels of skin barrier-related proteins such as filaggrin, involucrin, loricrin, occludin, and zonula occludens-1 (ZO-1) were increased by EGF treatment. These beneficial effects of EGF on AD may be mediated by EGF regulation of Th1/Th2-mediated cytokines, mast cell hyperplasia, and protease activated receptor-2 (PAR-2) and thymic stromal lymphopoietin (TSLP), which are triggers of AD. Taken together, our findings suggest that EGF may potentially protect against AD lesional skin via regulation of skin barrier function and immune response.

AD is a multifactorial skin disease characterized by complex interactions of innate and adaptive immune responses in individuals with genetic, pharmacological, and psychological predisposition. It is one of the most common chronic inflammatory skin diseases and is characterized by impaired epidermal barrier, eczematous lesions, pruritus, dry skin, abnormal immune responses, and immunoglobulin (Ig) E-mediated allergies to various exogenous antigens. When type 2 T cells are activated, cytokines such as interleukin (IL)-4, IL-5, IL-10, and IL-13 are secreted to strengthen the humoral immune response. IL-4 also plays a role in suppressing the function of type 1 T cells. Allergic reaction caused by an imbalance between type 1 and type 2 T cells is believed to cause AD. Other immune cells are also thought to be involved in AD. For instance, mast cells, which are major effector cells of IgE-mediated hypersensitivity reactions, are key factors in the pathogenesis of AD because they are allergen activated through the high-affinity IgE receptor. Mast cells are regulatory cells in Th2-dominant immune responses. Histamine is a major mediator released from mast cells that mediates pruritus by binding to the histamine H1 receptor in the dermis. Activation of mast cells also causes the release of tryptase, which in turn activates PAR-2, localized on C fiber nerve terminals. Activated C fibers transmit this information to the central nervous system, where the sensation of itch is perceived.
The epidermal growth factor receptor (EGFR) signaling pathway is crucial in skin development and homeostasis\textsuperscript{10}. The EGFR family comprises multiple mediators, including transforming growth factor-\(\alpha\), amphieregulin, heparin binding-EGF, and epiregulin, all of which regulate keratinocyte biology\textsuperscript{11,12}. Recent studies have shown the importance of EGF as a potential therapeutic target for maintaining intestinal epithelial health and inducing recovery of damaged epithelium\textsuperscript{11,12}. In addition, EGFR ligands have been found to be upregulated in chronic inflammatory skin disorders, such as psoriasis, atopic dermatitis, and allergic contact dermatitis\textsuperscript{13}. EGF facilitates epidermal cell regeneration and plays an essential role in the process of dermal wound healing by stimulating the proliferation and migration of keratinocytes. EGF treatment can stabilize mast cell degranulation, thereby reducing the release of granular products in gastric mucosal lesions of rats\textsuperscript{14}. Additionally, production of IL-17A and expression of IL-6 and IL-1\(\beta\) in allergen-induced AD skin have been shown to be attenuated by EGF treatment\textsuperscript{15}. However, the clinical effects and mechanisms of EGF have not been fully elucidated.

In the present study, we evaluated the effects of EGF on AD and propose a mechanism by which EGF regulates allergic inflammation both systemically and at the lesional level. Our findings indicate that EGF upregulates epidermal proteins and downregulates TSLP-mediated mast cell and Th2 cell activation to reduce AD symptoms in NC/Nga mice with DNCB-induced AD.

### Results

#### Epidermal growth factor has a robust protective effect against DNCB-induced atopic dermatitis in NC/Nga mice.

To investigate the effect of EGF on AD in our murine model, we induced inflammation of ear and dorsal skin of NC/Nga mice using DNCB (Fig. 1A). Topical application of DNCB produced AD-like lesions, including edematous erythema with scratching marks and dryness. Seven days after sensitization, the ear and dorsal skin of NC/Nga mice were re-sensitized with 0.4% DNCB and were treated with PRT 0.1%, EGF 1 ppm, or EGF 5 ppm for 2 weeks. PRT 0.1% is a well-known treatment for immune-mediated skin disorder\textsuperscript{16} and was used as a therapeutic control. Treatment with EGF suppressed DNCB-induced AD-like skin inflammation (Fig. 1B,C). Treatment with EGF 1 ppm or EGF 5 ppm significantly reduced ear thickness on day 21 compared to the control (Fig. 1D). In addition, EGF decreased dermatitis score of DNCB-induced skin lesions on days 14 and 21 in a dose-dependent manner (Fig. 1E). AD-like lesions showed hyperkeratosis and hyperplasia of the epithelium. H&E staining showed that the epidermal thickness of the ear and dorsal skin was attenuated by treatment with EGF and PRT 0.1% (Fig. 1B-E). Thicker epidermis and dermis were observed in skin lesions of the control group. However, EGF 1 and 5 ppm significantly reduced the epidermal thickness of the ear and dorsal skin compared to the control group. Taken together, these findings suggest that topical administration of EGF protects against DNCB-induced AD in NC/Nga mice.

#### Epidermal growth factor accelerates skin barrier repair in NC/Nga mice with DNCB-induced atopic dermatitis.

To evaluate skin barrier function, transepidermal water loss (TEWL) and moisture retention (corneometer assay) were measured in NC/Nga mice with DNCB-induced AD-like lesions. TEWL increased and moisture retention decreased during the 21-day experimental period. TEWL of AD-like skin lesion was significantly lower in the EGF 1 and 5 ppm groups on day 21 than the control group (Fig. 2A). In addition, the corneometer score was significantly higher in EGF 1 and 5 ppm group on day 21 than in the control group (Fig. 2B). Skin barrier proteins, including tight junction (TJ) components, are involved in epidermal barrier function and prevent TEWL\textsuperscript{17-20}. Skin barrier dysfunction could be due to defective epidermal proteins. To determine the effect of EGF on epithelial proteins in AD-like lesions, we performed immunoblotting experiments (Fig. 2C). Protein extracts were prepared from the dorsal skin of NC/Nga mice with DNCB-induced AD-like lesions. As shown in Fig. 2C, expression levels of epithelial proteins such as filaggrin, involucrin, loricrin, occludin, and ZO-1 were higher in the EGF- and PRT 0.1%-treated groups than in the control group. Furthermore, we measured the expression of filaggrin, involucrin, loricrin, and occludin in dorsal skin of mice suffering from DNCB-induced AD using immunohistochemistry (Fig. 2D,E). EGF administration increased the protein level of filaggrin, involucrin, loricrin, and occludin in DNCB-induced AD-like skin lesion. Collectively, these results support the hypothesis that EGF administration modulates skin barrier recovery by upregulating the production of epidermal proteins.

#### Epidermal growth factor inhibits mast cell infiltration and cytokine expression in NC/Nga mice with DNCB-induced atopic dermatitis.

We next focused on determining local infiltration by mast cells. Histamine, released by activated mast cells, allows immune cells to infiltrate into tissue by increasing the permeability of blood vessels\textsuperscript{21}. To reduce the allergic response in autoimmune diseases such as AD, it is necessary to control activated mast cells. To assess the inhibitory effect of EGF on mast cell hyperplasia in vivo, toluidine blue staining of the dorsal skin of DNCB-treated mice was performed to observe mast cell feature. The number of mast cells decreased significantly after administration of EGF compared to that in the control group (Fig. 3A,B). In addition, spleen weight was measured to determine immune system status (Fig. 3D). It is known that splenic enlargement or splenomegaly indicates abnormality of immune system function\textsuperscript{22}. Spleen weights of EGF-treated mice tended to decrease in a dose-dependent manner. EGF 1 ppm- or 5 ppm-treated groups had significantly lower spleen weights than the control group. This suggests that EGF can suppress the infiltration of mast cells and the immune response.

A major characteristic of AD is an increased serum level of IgE. In this study, levels of serum IgE were significantly lower in EGF-treated mice than in control mice (Fig. 3C). We next examined cytokine levels in dorsal skin and serum collected on day 21. We found that expression of the Th1 cytokine IFN-\(\gamma\) was lower in both skin lesion and serum of NC/Nga mice with DNCB-induced AD than in normal mice (Fig. 3E,F). However, administration of EGF 1 ppm and 5 ppm significantly increased IFN-\(\gamma\) level in AD-like skin lesions and serum of NC/Nga mice with DNCB-induced AD (Fig. 3E,F). Patients with AD produce less IFN-\(\gamma\) than controls\textsuperscript{23}. We found that levels of
the Th2 cytokines IL-4 and IL-13 were significantly enhanced by DNCB, while levels of IL-4 and IL-13 in AD-like skin lesion and serum were significantly decreased by EGF administration (Fig. 3E,F). Levels of IL-6 were also significantly lower in EGF-treated mice than control mice (Fig. 3E,F). In particular, the serum level of IL-6 in EGF 5 ppm-treated mice was three-fold lower than that of the control group. Expression of TNF-α in the EGF 5
Figure 2. EGF enhances skin barrier repair in DNCB-induced AD-like skin lesions in NC/Nga mice. (A) Measurements of TEWL and (B) corneometer score under similar conditions on days 7 and day 21. (C) Protein extracts were prepared from mouse dorsal skin and immunoblotted with anti-filaggrin, anti-involucrin, anti-loricrin, anti-occludin, anti-ZO-1, and anti-β-actin antibodies. Cropped images from the different parts were displayed. (D) Immunohistochemical staining of filaggrin, involucrin, loricrin, and occludin in skin equivalents from AD mouse at day 21. Dark brown dots (The red arrows) indicate positively stained cells. Images are representative of groups. Scale bar, 100 μm. (E) Morphometric analysis for immunostained area of the epidermis to each analyzed protein in relation to total area of the epidermis was performed quantitatively. Scale bar, 100 μm. Data are presented as mean ± SEM of changes in values. *p < 0.05, **p < 0.01 compared to controls.
Antipruritic and anti-inflammatory effect of EGF in NC/Nga mice with DNCB-induced AD. We next investigated the effect of EGF on DNCB-induced scratching behavior in NC/Nga mice. Spontaneous scratching behaviors in NC/Nga mice with AD-like skin lesions has been used to assess the effectiveness of anti-pruritis agents. We monitored the animals and note the scratching frequency of the nose, ears, and back. Scratching frequency was significantly higher in NC/Nga mice with DNCB-induced AD than in normal mice, whereas treatment with EGF reduced the frequency of scratching in these mice (Fig. 4A). The PAR-2-mediated TSLP production occurs pruritus and Th2 immune response in AD. In this study, the expression level of PAR-2 was significantly lower in EGF- and PRT 0.1%-treated groups than in the control group (Fig. 4B). In addition, we found that the level of TSLP was significantly lower in EGF- or PRT 0.1%-derived cytokine were measured using ELISA. Data are presented as mean ± SEM of changes in values. *p < 0.05, **p < 0.01 compared to controls.
We also found that the increase in protein level of p-ERK, which is involved in the induction of TSLP, in DNCB-induced mice was significantly attenuated by EGF treatment (Fig. 4B). Immunohistochemistry analysis also showed that expression levels of PAR-2 and TSLP were lower in paraffin section of skin biopsies, consistent with the results of immunoblot analysis (Fig. 4C,D). These results demonstrate that EGF can reduce the immune response by regulating PAR-2 and TSLP expression.

Discussion
In this study, we investigated the anti-AD potential of EGF by inducing AD-like skin lesions in NC/Nga mice using DNCB. The NC/Nga mouse model is a well-established spontaneous animal model of human AD. However, spontaneous AD-like lesions in this model are late onset and have a low incidence (<50%)28. Thus, we used 2,4-dinitrochlorobenzene (DNCB), a commonly used allergenic chemical, to induce AD in this study. When mouse skin is repeatedly exposed to DNCB, it exhibits hyperkeratosis, a thick epidermis, and infiltration of lymphocytes and mast cells, similar to human AD symptoms29. We found that topical application of EGF attenuated DNCB-induced AD-like skin lesions in NC/Nga mice. EGF treatment improved scratching frequency, hyperkeratosis, ear and epidermal thickness, dermatitis score, and scratching behaviors of DNCB-treated NC/Nga mice. Moreover, DNCB-induced mast cell infiltration and serum IgE levels were reduced following EGF application.

Figure 4. EGF attenuates protein expression of PAR-2 and TSLP in DNCB-induced AD-like skin lesions in NC/Nga mice. (A) Scratching frequency was evaluated on day 21. Western blot analysis and immunohistochemistry were performed for PAR-2 and TSLP in skin biopsies from NC/Nga mice with DNCB-induced AD-like skin lesions. (B) Lysates were immunoblotted with anti-phospho-ERK, anti-ERK, anti-PAR-2, anti-TSLP, and anti-β-actin antibodies. Cropped images from the different parts were displayed. (C) Paraffin sections of skin biopsies from DNCB-induced AD-like skin lesions were immunostained with anti-PAR-2 and anti-TSLP antibodies. Dark brown dots (The red arrows) indicate positively stained cells. Images are representatives of groups. Scale bar, 100 μm. (D) Morphometric analysis for immunostained area of the epidermis to each analyzed protein in relation to total area of the epidermis was performed quantitatively. Data are presented as mean ± SEM of changes in values. *p < 0.05; **p < 0.01 compared to controls.
We also observed that EGF restored epidermal water loss by upregulating the expression of skin barrier-related proteins. In addition, we found that EGF treatment balanced the Th1/Th2 immune response and reduced levels of PAR-2 and TSLP in DNCB-treated NC/Nga mice. These findings suggest that topical administration of EGF may be useful for the treatment of AD.

AD is characterized by skin barrier defects as well as increased immune responses. Previous reports showed that TEWL of lesional skin was significantly increased in patients who had a disturbed skin barrier18–20. Many consequences of a dysfunctional skin barrier can be explained by defective epidermal proteins. In both lesional and nonlesional skin of patients with AD, filaggrin mutation has been shown to contribute to increased TEWL, a measure of skin barrier integrity17–19. Filaggrin is a key protein that supports terminal differentiation and skin barrier formation. Filaggrin-deficient mice have increased antigen penetration33, and filaggrin-deficient patients have markedly increased surface pH of skin34. In addition, changes in stratum corneum lipids in nonlesional skin have been found to be associated with reduced barrier function15,36. “Flaky tail” mice deficient in profilaggrin exhibit reduced occludin, E-cadherin, and loricrin expression, as well as decreased EGFR37, and humans with FLG mutations show decreased expression of the TJ proteins occludin and ZO-138. In the present study, EGF treatment resulted in recovery of levels of the epidermal proteins filaggrin, involucrin, loricrin, occludin, and ZO-1 to control levels. Moreover, EGF treatment significantly decreased TEWL and increased corneometer score compared to the controls. Interestingly, a previous study demonstrated that EGF restored barrier defects induced by H2O2.

The application of H2O2-induced barrier disruption of TJs in Caco-2 cells, but EGF prevented disruption of the actin cytoskeleton and dissociation of occludin and ZO-1 through interaction with occludin35. Furthermore, EGF differentially regulated the association of PP2A, which dephosphorylates occludin, with PKCδ, which phosphorylates occludin, required for the assembly of tight junctions in Caco-2 cells. EGF attenuated the increased binding of P2PA with occludin and decreased binding of PKCδ with occludin in H2O2-induced differentiated cells36. These protective effects of the skin barrier suggest that EGF treatment can inhibit allergen-induced derangement of keratinocyte functions.

Impaired skin barrier function increases the intake of allergens and causes inflammation. Inflammation can in turn reduce skin barrier function. For example, a decrease in filaggrin expression was observed after treatment of epidermal models with TNF-α and Th2 cytokines41. In addition, keratinocytes that differentiate in the presence of IL-4 and IL-13 are known to reduce filaggrin level42. Cytokines are other triggers of AD, and AD inflammation is associated with increased levels of serum IgE and inflammatory infiltrates such as lymphocytes, mast cells, dendritic cells, and macrophages that produce inflammatory cytokines such as IL-4, IL-13, and IL-31. While the Th2 cytokine IL-4 is important in acute atopic eczema, the Th1 and Th17 cytokines IFN-γ, IL-17, and IL-22 predominate in chronic eczema35. Under normal condition, Th1 and Th2 responses are balanced by cytokine regulation. IL-4 inhibits the generation of Th1-cells, whereas IFN-γ inhibits IgE synthesis and Th2 expansion42. In acute AD, Th2 lymphocytes produce many cytokines that can increase IgE production including IL-4, IL-6, and IL-1342. IgE, in turn, activates mast cells and basophils. Activation of mast cells induces the release of many pro-inflammatory cytokines such as IL-4, IL-6, and TNF-α from the granules of mast cells43. A recent study showed that EGF treatment had protective role against AD by suppressing allergen-induced IL-6 production by keratinocytes37. In addition, upregulation of EGFR and its ligand expression have been found in chronic inflammatory skin disorders including AD44. We demonstrated that EGF can inhibit mast cell infiltration and its allergic effects. Moreover, EGF decreased levels of IgE and proinflammatory cytokines including TNF-α, IL-6, IL-4, and IL-13 in serum and dorsal AD-like lesions. In contrast, EGF treatment significantly increased serum and dorsal levels of IFN-γ. These effects may be related to the reduction in spleen weight caused by EGF treatment. These results demonstrate the potential of EGF treatment for attenuating immune responses by regulating T-lymphocyte balance and mast cell infiltration.

PAR-2 is an important biological regulator of inflammation, the immune response, and the release of cytokines and growth factors in the skin. Some of these effects might be mediated, at least in part, by activation of PAR-2, a molecule that regulates skin homeostasis and disease45. Previous studies have shown a correlation between TSLP expression and PAR-2 activity in the skin of AD mouse models and in patients with atopic disease36,46. In addition, PAR-2 activation can lead to robust expression of TSLP in keratinocytes39. In particular, Th2 cytokines are known to be triggered by TSLP produced by keratinocytes50,51. TSLP is one of several candidates that can trigger Th2 commitment by activating DCs to induce differentiation of naive T cells to Th2 cells. In addition, mast cell tryptase might be a crucial mediator of itch by activating PAR-2 in sensory nerves47. TSLP released from keratinocytes acts directly on sensory nerves to trigger robust itch-evoked scratching47. To better understand the mechanism of allergic inflammation and pruritus, we determined the expression levels of PAR-2 and TSLP in DNCB-treated NC/Nga mice. These findings suggest that transactivation of EGFR by TNF-α results in TSLP induction in keratinocytes51. However, amphiregulin, one of the EGFR ligands, suppressed dermatitis via EGFR52 and epiregulin deficiency lead to chronic skin inflammation46. Our data showed that EGF treatment has a remarkable downregulatory effect on TSLP expression in the skin. These data support that EGF can act as an immunoregulator by decreasing TSLP levels in AD-like skin tissues. Interestingly, the prolonged use of EGFR tyrosine kinase inhibitors is associated with a common side effect of skin inflammatory rash in cancer patients57,58. In addition, blockage of the EGFR enhances skin inflammation by inducing chemokine expression59,60. Similar to these studies, we found that the expression of Th2 cytokines and TSLP reduced after EGF treatment. In this regard, although EGF (5ppm) did not...
show a better effect than EGF (1ppm) treatment on PAR-2 and TSLP expression, our findings indicate that EGF can ameliorate itching as well as the immune response by inhibiting PAR-2 and TSLP expression in AD lesions.

Results of this study demonstrate that EGF has anti-AD potential. Topical administration of EGF has been successfully used to treat a variety of peripheral tissues wounds. Therapeutic efficacy and excellent tolerance of EGF have been proven. Administration of EGF resulted in improved Th1/Th2 balance and inhibited mast cell hyperplasia, a major process in the induction of atopic dermatitis. It also ameliorated DNCB-induced AD-like skin inflammation in mice. Our results suggest that EGF can improve AD symptoms, although further research is necessary to clarify the effect of EGF on the sensory neurons of AD-like skin.

Materials and Methods

Animals. Seven-week-old male NC/Nga mice were purchased from Central Laboratory Animal Inc. (Seoul, Korea) and housed in an air-conditioned room under specific pathogen-free conditions at 24 ± 2°C and 55 ± 15% humidity, with a 12 h light–dark cycle. Mice were placed individually in separate cages and fed ad libitum. All procedures involving animals were conducted in accordance with the Guide for the Care and Use of Laboratory Animals (Washington, DC, USA) and were approved by the Institutional Animal Care and Use Committee of Chung-Ang University in Korea (2017-00011).

Induction of AD-like skin lesions. AD-like skin lesions were induced in 8-week-old male NC/Nga mice using DNCB as described in a previous study8. After 1 week of acclimation, mice were randomly divided into five groups (n = 8 per group): (1) a non-treated control group (normal), (2) a DNCB-treated group (negative control), (3) DNCB-treated + proteo 0.1% group [100μg per mouse; PRT 0.1%], (4) a DNCB-treated + 1 ppm EGF group [200μl (0.2μg) per mouse; EGF 1 ppm] and (5) a DNCB-treated + 5 ppm EGF group [200μl (1μg) per mouse; EGF 5 ppm]. The dorsal hair of mice was shaved with an electric clipper before sensitization. For the sensitization process, 200μl of 1% DNCB dissolved in an acetone:saline mixture (3:1) was applied to the dorsal skin, and 10μl was applied to right ear on days 1 and 4. Left ear is normally used as internal control in each animal, to assess the increase in ear thickness of the right ear. Seven days after dorsal hair removal, 0.4% DNCB was applied to challenge the dorsal skin (200μl) and right ear (10μl) three times a week for 2 weeks (days 7–21). EGF dissolved in phosphate-buffered saline (PBS)/polyethylene glycol (PEG) (3:7, 1 and 5 ppm, 200μl/mouse) or tacrolimus (0.1% protopic ointment, Astellas Pharma, Tokyo, Japan; 100μg/mouse) was topically applied to the dorsal skin and ear daily for 2 weeks (days 7–21). At the end of the experiments, animals were anesthetized with zoletil (50mg/kg) and xylazine (10mg/kg). The experimental design is summarized in Fig. 1A. EGF was manufactured by Daewoong Pharmaceutical (Seoul, Korea).

Measurement of total dermatitis score, ear thickness, and epidermal thickness. Dermatitis scores were measured once a week using criteria described previously with slight modifications8. Total skin severity score (maximum score: 12) were defined as the sum of individual scores (0, no symptoms; 1, mild; 2, moderate; 3, severe) for each of the following four signs and symptoms: erythema/hemorrhage, edema, excoriation/erosion, and scaling/dryness. Clinical symptoms were measured using images captured weekly with a digital camera (Canon 3000D, Canon Inc., Tokyo, Japan) for 3 weeks. In addition, mouse ear thickness and epidermal thickness of 10 randomly selected area in 3 sections for each animal was measured using hematoxylin and eosin (H&E) staining and Image-Pro Plus software (version 6.0 for Windows) with the aid of a microscope (DM750, Leica, Wetzlar, Germany). Assessments were performed in a blinded manner.

Scratching behavior. To investigate AD-like behavioral changes, we measured and recorded the frequencies of mouse rubbing of nose, ears, and dorsal skin with hind paws for 10 min period immediately after DNCB sensitization on day 21.

Measurement of serum IgE and inflammatory cytokines. Blood and dorsal skin were collected from NC/Nga mice at 3 weeks post-treatment and stored at -80°C until use. Serum samples were obtained by centrifugation of blood at 3000 g for 15 min at 4°C. The total amount of IgE in the serum was measured using an enzyme-linked immunosorbent assay (ELISA) kit (Shibayagi, Gunma, Japan) according to the manufacturer’s instructions. Serum levels of cytokines IL-4, IL-13, IL-6, TNF-α, and IFN-γ were also measured using ELISA kits (R&D Systems, Minneapolis, MN, USA).

Quantitative RT-PCR. Total RNA was extracted from dorsal skin using TRIzol (Invitrogen, CA, USA). First-strand cDNA synthesis from the total RNA template was performed with PrimeScript™ RT master mix (Takara, Tokyo, Japan). The resulting cDNA was subjected to real-time PCR using qPCR 2x PreMIX SYBR (Enzynomics, Seoul, Korea) and housed in an air-conditioned room under specific pathogen-free conditions at 24 ± 2°C and 55 ± 15% humidity, with a 12 h light–dark cycle. Mice were placed individually in separate cages and fed ad libitum.
Western blot analysis. Dorsal skin samples were harvested and stored at −80 °C. Protein lysates were prepared using lysis buffer [50 mM Tris–HCl (pH 8.0), 150 mM NaCl, 1 mM EDTA, 1% NP-40 and 0.25% deoxycholate] containing a protease inhibitor cocktail (Complete™, Roche, Mannheim, Germany). The amounts of protein in the lysates were quantitated using a Bio-Rad DC Protein Assay Kit II (Bio-Rad, Hercules, CA). After quantitation, equal amounts of protein were resolved on 10% SDS–PAGE gels and electrotransferred to polyvinylidene fluoride membranes (Millipore, Bedford, MA, USA). After blocking with 5% skim milk in Tris-buffered saline containing 0.5% Tween-20 (TBST), membranes were probed with anti-filaggrin (1:2500; ab24584; Abcam, Cambridge, UK), anti-involucrin (1:2500; ab668; Abcam), anti-loricrin (1:1000; sc-5562; Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-ZO-1 (1:1000; sc-10804; Santa Cruz Biotechnology), anti-p-ERK (1:2500; #9101; Cell Signaling Technology, Inc., Danvers, MA, USA), anti-ERK (1:2500; #9102; Cell Signaling Technology, Inc.), anti-PAR-2 (1:1000; sc-8205; Santa Cruz Biotechnology), anti-β-actin (1:1000; sc-47778; Santa Cruz Biotechnology) antibodies at 4 °C overnight. After washing, membranes were incubated with HRP-conjugated anti-mouse (1:10000; PI-2000; Vector Labs Inc., Burlingame, CA, USA) or anti-rabbit (1:10000; PI-1000, Vector Labs Inc., Burlingame, CA, USA) secondary antibodies. Immunoreactive signals were detected using enhanced chemiluminescence (ECL) reagents (Amersham Pharmacia, Piscataway, NJ, USA).

Transepidermal water loss (TEWL). The amount of TEWL in mouse dorsal skin was measured at 21–22 °C and 50–55% humidity using a skin evaporative water recorder (Tewameter TM300, Courage-Khazaka Electronics, Koln, Germany) and corneometer (Courage and Khazaka Electronic, Germany) at days 14 and 21. Values were recorded only after signal stabilization, which occurred approximately 30s after the probe was placed on the skin. Data were analyzed with a microprocessor and are expressed as g/m²/h.

Histological examination. To evaluate epidermal thickening, the ear and dorsal skin of each mouse was obtained on day 21 and fixed in 10% neutral buffered formalin. Tissues were embedded in paraffin and sliced into 5-μm-thick sections. Sections were then transferred to probe-on-plus slides (Thermo Scientific, Carlsbad, CA, USA), and deparaffinized skin sections were stained with H&E. Mast cells in the skin were stained with toluidine blue. Some sections were stained for immunohistochemical markers using anti-filaggrin (1:1000; ab24584; Abcam), anti-involucrin (1:1000; ab668; Abcam), anti-loricrin (1:1000, ab85679, Abcam), anti-occludin (1:1000; 33-1500; Invitrogen), anti-PAR-2 (1:1000; sc-8205, Santa Cruz Biotechnology), and anti-TSLP (1:2500; NB110-55234; Novus Biologicals, Littleton, CO, USA), and anti-β-actin (1:1000; sc-47778; Santa Cruz Biotechnology) antibodies at 4 °C overnight. After washing, membranes were incubated with HRP-conjugated anti-mouse (1:10000; PI-2000; Vector Labs Inc., Burlingame, CA, USA) or anti-rabbit (1:10000; PI-1000, Vector Labs Inc., Burlingame, CA, USA) secondary antibodies. Immunoreactive signals were detected using enhanced chemiluminescence (ECL) reagents (Amersham Pharmacia, Piscataway, NJ, USA).

Statistical analysis. Data are presented as means ± standard error of the mean (SEM) for three independent experiments. Statistical analyses were performed using SPSS software version 10.0 (SPSS Inc., Chicago, IL, USA) program. For multiple comparisons, one-way analysis of variance was used with post hoc Bonferroni test. We considered P values <0.05 statistically significant. Significance levels are designated as follows: *P < 0.05; **P < 0.01.

References
1. Boguniewicz, M. & Leung, D. Y. Atopic dermatitis: a disease of altered skin barrier and immune dysregulation. *Immunological reviews* **242**, 233–246 (2011).
2. Lee, H.-J. & Lee, S.-H. Epidermal permeability barrier defects and barrier repair therapy in atopic dermatitis. *Allergy, asthma & immunology research* **6**, 276–287 (2014).
3. Leung, D. Y. & Soter, N. A. Cellular and immunologic mechanisms in atopic dermatitis. *Journal of the American Academy of Dermatology* **44**, S1–S12 (2001).
4. Galli, S. J., Maurer, M. & Lantzi, C. S. Mast cells as sentinels of innate immunity. *Current opinion in immunology* **11**, 53–59 (1999).
5. Yosipovitch, G., Greaves, M. W. & Schmelz, M. Itch. *The Lancet* **361**, 690–694 (2003).
6. Monika, J., Csaba, K. & Rodeck, U. The EGF receptor—an essential regulator of multiple epidermal functions. *European Journal of Dermatology* **10** (2000).
7. Oda, K., Matsuoka, Y., Funahashi, A. & Kitano, H. A comprehensive pathway map of epidermal growth factor receptor signaling. *Molecular systems biology* **1** (2005).
8. Berlanga-Acosta, J. et al. Epidermal growth factor receptor in clinical practice—a review of its biological actions, clinical indications and safety implications. *International wound journal* **6**, 331–346 (2009).
9. Repertinger, S. K. et al. EGFR enhances early healing after cutaneous incisional wounding. *Journal of Investigative Dermatology* **123**, 982–989 (2004).
10. Werner, S. & Grosse, R. Regulation of wound healing by growth factors and cytokines. *Physiological reviews* **83**, 835–870 (2003).
11. Egger, B., Büchter, M., Lakshmanan, J., Moore, P. & Eysselein, V. Mice Harboring a Defective Epidermal Growth Factor Receptor- (Waved-2) Have an Increased Susceptibility to Acute Dextran-Sulfate-induced Colitis. *Scandinavian journal of gastroenterology* **35**, 1181–1187 (2000).
12. TROYER, K. L. et al. Growth retardation, duodenal lesions, and aberrant ileum architecture in triple null mice lacking EGF, amphiregulin, and TGF-α. *Gastroenterology* **121**, 68–78 (2001).
13. Pastore, S., Mascia, F., Mariani, V. & Girolomoni, G. The epidermal growth factor receptor system in skin repair and inflammation. *Journal of Investigative Dermatology* **128**, 1365–1374 (2008).
14. Erkasap, S. et al. Mast cell stabilizer and antioxidant effects of epidermal growth factor (EGF) on gastric mucosal injury induced by ethanol in rats. *Chinese Journal of Physiology* **48**, 1 (2003).
15. Zhang, Z., Xiao, C., Gibson, A. M., Bass, S. A. & Hershey, G. K. K. EGFR signaling blunts allergen-induced IL-6 production and Th17 responses in the skin and attenuates development and relapse of atopic dermatitis. *The Journal of Immunology* **192**, 859–866 (2014).
16. Lazarous, M. & Kerdel, F. A. Topical tacrolimus protopic. Drugs Today (Barc) 38, 7–15 (2002).
17. Werner, Y. & Lindberg, M. Transepidermal water loss in dry and clinically normal skin in patients with atopic dermatitis. Acta Derm Venereol 65, 102–105 (1985).
18. Hon, K. L., Wong, K. Y., Leung, T. F., Chow, C. M. & Ng, P. C. Comparison of skin hydration evaluation sites and correlations among skin hydration, transepidermal water loss, SCORAD index, Nottingham Eczema Severity Score, and quality of life in patients with atopic dermatitis. American journal of clinical dermatology 9, 85–90 (2008).
19. Nemoto-Hasebe, I. et al. Clinical severity correlates with impaired barrier in filaggrin-related eczema. The Journal of investigative dermatology 129, 682–689, https://doi.org/10.1038/jid.2008.280 (2009).
20. Fallon, P. G. et al. A homozygous frameshift mutation in the mouse Flg gene facilitates enhanced percutaneous allergen priming. Nature genetics 41, 602–608, https://doi.org/10.1038/ng.359 (2009).
21. Monroe, E. W., Daly, A. F. & Shalhoub, R. F. Appraisal of the validity of histamine-induced wheal and flare to predict the clinical efficacy of antihistamines. Journal of allergy and clinical immunology 99, 5798–5806 (1997).
22. Schneider, L. C., Baz, Z., Zarcone, C. & Zurakowski, D. Long-term therapy with recombinant interferon-gamma (rHNF–γ) for atopic dermatitis. Annals of Allergy, Asthma & Immunology 80, 263–266 (1998).
23. Takano, N., Arai, I. & Kurachi, M. Analysis of the spontaneous scratching behavior by NC/Nga mice: a possible approach to evaluate antipruritics for subjects with atopic dermatitis. European journal of pharmacology 471, 223–228 (2003).
24. Wilson, S. R. et al. The epithelial cell-derived atopic dermatitis cytokine TSLP activates neurons to induce itch. Cell 155, 285–295 (2013).
25. Briot, A. et al. Kallikrein 5 induces atopic dermatitis–like lesions through PAR2-mediated thymic stromal lymphopoietin expression in Netherton syndrome. Journal of Experimental Medicine 206, 1135–1147 (2009).
26. Tu, H. S., Angkasewkini, P., Chang, S. H., Chung, Y. & Dong, C. Protease allergens induce the expression of IL-25 via Erk and p38 MAPK pathway. Journal of Korean medical science 25, 829–834 (2010).
27. Shiohara, T., Hayakawa, J. & Mizukawa, Y. Animal models for atopic dermatitis: are they relevant to human disease? Journal of dermatological science 36, 1–9 (2004).
28. Lee, K. S. et al. A novel model for human atopic dermatitis: application of repeated DNCB patch in BALB/c mice, in comparison with NC/Nga mice. Laboratory Animal Research 26, 95–102 (2010).
29. Ring, J. et al. Skin surface pH, stratum corneum hydration, trans-epidermal water loss and skin roughness related to atopic eczema and skin dryness in a population of primary school children: clinical report. Acta Dermatovenerologica 80, 188–191 (2000).
30. Gruber, R. et al. Diverse regulation of claudin-1 and claudin-4 in atopic dermatitis. The American journal of pathology 185, 2777–2789 (2015).
31. Lee, C. H. et al. Transepidermal water loss, serum IgE and α-endorphin as important and independent biological markers for development of itch intensity in atopic dermatitis. British Journal of Dermatology 154, 1100–1107 (2006).
32. Kawasaki, H. et al. Altered stratum corneum barrier and enhanced percutaneous immune responses in filaggrin–null mice. Journal of allergy and clinical immunology 129, 1538–1546, e1536 (2012).
33. Juungest, J. et al. Stratum corneum lipids, skin barrier function and filaggrin mutations in patients with atopic eczema. Allergy 65, 911–918 (2010).
34. Janssens, M. et al. Increase in short-chain ceramides correlates with an altered lipid organization and decreased barrier function in atopic eczema patients. Journal of lipid research 53, 2755–2766 (2012).
35. Smeden, J. et al. The importance of free fatty acid chain length for the skin barrier function in atopic eczema patients. Experimental dermatology 23, 45–52 (2014).
36. Nakai, K. et al. Reduced expression of epidermal growth factor receptor, E-cadherin, and occludin in the skin of flaky tail mice is due to filaggrin and loricrin deficiencies. The American journal of pathology 181, 969–977 (2012).
37. Gruber, R. et al. Filaggrin genotype in ichthyosis vulgaris predicts abnormalities in epidermal structure and function. The American journal of pathology 178, 2252–2263 (2011).
38. Basuroy, S., Seth, A., Elias, B., Naren, A. P. & Rao, R. MAPK interacts with occludin and mediates EGFR-induced prevention of tight junction disruption by hydrogen peroxide. Biochemical Journal 393, 69–77 (2006).
39. Aggarwal, S., Suzuki, T., Taylor, W. L., Bhargava, A. & Rao, R. K. Contrasting effects of ERK on tight junction integrity in differentiated and under–differentiated Caco-2 cell monolayers. Biochemical Journal 433, 51–63 (2011).
40. Danso, M. O. et al. TNF-α and IL-2 cytokines induce atopic dermatitis–like features on epidermal differentiation proteins and stratum corneum lipids in human skin equivalents. Journal of Investigative Dermatology 134, 1941–1990 (2014).
41. Howell, M. D. et al. Cytokine modulation of atopic dermatitis filaggrin skin expression. Journal of Allergy and Clinical Immunology 124, R7–R12 (2009).
42. Eyerich, K. & Novak, N. Immunology of atopic eczema: overcoming the Th1/Th2 paradigm. Allergy 68, 974–982 (2013).
43. Boguniewicz, M. et al. Recombinant gamma interferon in treatment of patients with atopic dermatitis and elevated IgE levels. The American journal of medicine 88, 365–370 (1990).
44. Valet, R. et al. Autoallergy: a pathogenic factor in atopic dermatitis? Journal of allergy and clinical immunology 105, 432–437 (2000).
45. Theoharides, T. C., Kempuraj, D., Takano, N. et al. Trypholysin attenuates DNCB-induced atopic dermatitis–like symptoms in NC/Nga mice. PLoS One 9, e104938 (2014).
46. Soumelis, V. et al. Human epithelial cells trigger dendritic cell–mediated allergic inflammation by producing TSLP. Nature immunology 3, 673–680 (2002).
47. Yosipovitch, G. & Fleischer, A. B. Itch associated with skin disease. American journal of clinical dermatology 4, 617–622 (2003).
48. Jiang, Y. et al. UVB induces IFN-α-dependent TSLP expression via the JNK and ERK pathways. Journal of Investigative Dermatology 133, 2601–2608 (2013).
49. Segawa, R. et al. EGFR transactivation is involved in TNF-α–induced expression of thymic stromal lymphopoietin in human keratinocyte cell line. Journal of dermatological science 89, 290–298 (2018).
50. Taiss, D. M. et al. Amphiregulin enhances regulatory T cell-suppressive function via the epidermal growth factor receptor. Immunity 37, 275–284 (2013).
51. Shirasawa, S. et al. Dermatitis due to epiregulin deficiency and a critical role of epiregulin in immune-related responses of keratinocyte and macrophage. Proceedings of the National Academy of Sciences of the United States of America 101, 13921–13926 (2004).
57. Hu, J. C., Sadeghi, P., Pinter-Brown, L. C., Yashar, S. & Chiu, M. W. Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management. *Journal of the American Academy of Dermatology* **56**, 317–326 (2007).

58. Agero, A. L. C. *et al*. Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. *Journal of the American Academy of Dermatology* **55**, 657–670 (2006).

59. Mascia, F., Mariani, V., Girolomoni, G. & Pastore, S. Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation. *The American journal of pathology* **163**, 303–312 (2003).

60. Yamaki, M., Sugiura, K., Muro, Y., Shimoyama, Y. & Tomita, Y. Epidermal growth factor receptor tyrosine kinase inhibitors induce CCL2 and CCL5 via reduction in IL-1R2 in keratinocytes. *Experimental dermatology* **19**, 730–735 (2010).

61. Fujii, Y., Takeuchi, H., Sakuma, S., Sengoku, T. & Takakura, S. Characterization of a 2,4-dinitrochlorobenzene-induced chronic dermatitis model in rats. *Skin pharmacology and physiology* **22**, 240–247 (2009).

**Acknowledgements**

This research was supported by Daewoong Pharmaceutical (Seoul, Korea).

**Author Contributions**

B.J.K., J.N., Y.J.K., M.J.C. and D.H.B. designed research; Y.J.K., M.J.C., B.C.L. and D.H.B. conducted research; B.J.K., J.N., Y.J.K., M.J.C., D.H.B., E.J.K., S.W.A., M.J.K. and G.R.A. analyzed data; B.J.K., J.N. and Y.J.K. prepared figures; B.J.K. and J.N. wrote the paper. B.J.K. and J.N. had primary responsibility for final content. All authors read and approved the final manuscript.

**Additional Information**

**Competing Interests:** The authors declare no competing interests.

**Publisher’s note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2018